Статья
ФИКСИРОВАННАЯ НИЗКОДОЗОВАЯ КОМБИНАЦИЯ ЛИЗИНОПРИЛА И ГИДРОХЛОРТИАЗИДА В ПРОФИЛАКТИКЕ СЕРДЕЧНО-СОСУДИСТЫХ СОБЫТИЙ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ
Обсуждаются особенности механизма действия и клинического применения фиксированной низкодозовой комбинации лизиноприла и гидрохлортиазида. Показана целесообразность комбинирования ингибитора АПФ и тиазидового диуретика, что обусловлено более эффективным контролем артериального давления, потенцированием органопротективного действия и снижением риска побочных эффектов. Представлены результаты клинических исследований эффективности и безопасности препарата у больных артериальной гипертонией с различными сопутствующими заболеваниями.
1. Balanova Yu.A., Vilkov V.G., Dotsenko A.N. et al. Results of the second stage of monitoring the epidemiological situation of hypertension in the Russian Federation (2005-2007) within the Federal Target Program “Prevention and treatment of hypertension”. Information and statistical book. M.: GNITs PM; 2008. Russian (Баланова Ю.А., Вилков В.Г., Доценко А.Н. и др. Результаты второго этапа мониторинга эпидемиологической ситуации по артериальной гипертонии в Российской Федерации (2005-2007 гг.) в рамках Федеральной целевой программы “Профилактика и лечение артериальной гипертонии”. Информационно-статистический сборник. М.: ГНИЦ ПМ; 2008).
2. National guidelines for diagnosis and treatment of hypertension. The Experts Committee of RMSAH and RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) prilozhenie 2:3-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Комитет экспертов РМОАГ и ВНОК. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2:3-32).
3. Ernst M.E., Gordon J.A.Diuretic therapy: key aspects in hypertension and renal disease. J Nephrol 2010; 23(5): 487 - 493
4. Turnbull F., Neal B., Algert C. et al. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165(12):1410–1419
5. Psaty B.M., Lumley T., Furberg C.D. et al.Health outcomes associated with various antihypertensive therapies used as firstline agents: a network meta-analysis. JAMA 2003;289(19):2534-44.
6. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
7. Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pres�sure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-1535
8. de Carvalho J.G., Dunn F.G., Lohmoller G., Frohlich E.D. Hemodynamic correlates of prolonged thiazide therapy: comparison of responders and nonresponders. Clin Pharmacol Ther 1977;22(6):875-80
9. Hughes A.D. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst 2004;5(4):155-60
10. Stamler R., StamlerJ., Grimm R. et al. Nutritional therapy for high blood pressure: finalreport of a fouryear randomized controlled trial — the Hypertension Control Program. JAMA 1987;257(11): 1484-91.
11. Uretsky B.F., Shaver J.A., Liang C.S. et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin-converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional and biochemicalresponses. Am Heart J 1988;116(2 Pt 1):480–488.
12. Gilbert E.M., et al. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation 1993;88(2);472-480.
13. Boger-Megiddo I., Heckbert S.R., Weiss N.S. et al. Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 2010;340:c103
14. Patel B.V., Remigio-Baker R.A., Thiebaud P. et al. Improved persistence and adherence to diuretic fixeddose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008; 9:61.
15. MotwaniJ.G. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy fortreatment of hypertension. JRAAS 2002;3(2):72-8.
16. Keinänen-Kiukaanniemi S., Rasmusen M., Pekkarinen T. et al. Effects of lisinopril or lisinopril/hydrochlorothiazide compared with adjusting of previous medication and intensifying non-pharmacological treatment in patients with mild to moderate hypertension. Arzneimittelforschung 1997;47(2):144-50.
17. Epstein M., Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996;156(17): 1969-1978.
18. Frank J. Managing hypertension using combination therapy. Am Fam Physician 2008;77(9): 1279-1286.
19. Gerc V., Begović B., Vehabović M. et al. Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. Bosn J Basic Med Sci 2007;7(4):377-82.
20. Gerc V., Begović B., Vehabović M. et al. Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn J Basic Med Sci 2008;8(3):214-9.
21. Boydak B., Nalbantgil S., Yilmaz H. et al. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension. Saudi Med J 2004;25(12):1975-8.
22. L'Allier P.L., Ducharme A., Keller P.F. et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44(1):159-64.
23. Prisant L. M., Neutel J. M., Ferdinand K. et al. Hall, and M. R. Weir. Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc 1999; 91(1): 40–48.
24. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427
25. Lee A.F., Dick J.B., Bonnar C.E., Struthers A.D. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci 1999;96(5):441-8
26. Greenberg A. Diuretic complications. Am J Med Sci 2000;319(1):10-24.
27. The ALLHAT Collaborative Research Group Major Outcomes in High-Risk Hypertensive Patients Randomized to ACE Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23):2981-2997.
28. Whelton P.K., Barzilay J., Cushman W.C. et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165(12): 1401-1409
29. Chrysant S.G. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med 1994;154(7): 737-43.
30. Zillich A.J., Garg J., Basu S. et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48(2):219-224.
31. Koster J.C., Remedi M.S., Masia R. et al. Expression of ATP-insensitive KATP channels in pancreatic beta-cells underlies a spectrum of diabetic phenotypes. Diabetes 2006;55(11): 2957-2964.
32. Shafi T., Appel L.J., Miller E.R. 3rd et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008;52(6):1022-1029.
33. Reisin E., Weir M.R., Falkner B. et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30 (1 Pt 1):140-145.
34. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al. Effects of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351(9095): 28-31.
35. Henriksen E.J., Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 2003;196(1):171-9.
36. Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274): 1440-4.
37. Bakris G.L., Toto R.D., McCullough P.A. et al. Effects of differentACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008;73(11):1303-1309.
38. Rigaud A.S., Forett B. Hypertension in older adults. J Gerontol A Biol Sci Med Sci 2001;56(4): M217-25.
39. Lipsitz L.A., Gagnon M., Vyas M. et al. Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. Hypertension 2005; 45(2): 216-221.